Navigation Links
UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
Date:7/1/2013

Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle cell disease to treat the disease. The study was led by Dr. Donald Kohn, professor of pediatrics and of microbiology, immunology and molecular genetics.

Sickle cell disease causes the body to produce red blood cells that are formed like the crescent-shaped blade of a sickle, which hinders blood flow in the blood vessels and deprives the body's organs of oxygen.

Kohn introduced an anti-sickling gene into the hematopoietic stem cells to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle. The breakthrough gene therapy technique for sickle cell disease is scheduled to begin clinical trials by early 2014. The study was published online today ahead of press in the Journal of Clinical Investigation.

Kohn's gene therapy approach, which uses hematopoietic stem cells from a patient's own blood, is a revolutionary alternative to current sickle cell disease treatments as it creates a self-renewing normal blood cell by inserting a gene that has anti-sickling properties into hematopoietic stem cells. This approach also does not rely on the identification of a matched donor, thus avoiding the risk of rejection of donor cells. The anti-sickling hematopoietic stem cells are transplanted back into the patient's bone marrow and multiply the corrected cells that make red blood cells without sickling.

"The results demonstrate that our technique of lentiviral transduction is capable of efficient transfer and consistent expression of an effective anti-sickling beta-globin gene in human sickle cell disease bone marrow progenitor cells, which improved the physiologic parameters of the resulting red blood cells," Kohn sa
'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology news :

1. Neuroblastoma: Autophagy protects from chemotherapy
2. Dendritic cell therapy improves kidney transplant survival, Pitt team says
3. No danger of cancer through gene therapy virus
4. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
5. New sickle cell anemia therapy advances to Phase II clinical trials
6. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
7. Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration
8. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
9. Researchers reveal new more precise method of performing electroconvulsive therapy
10. Discovery may help prevent chemotherapy-induced anemia
11. Penn receives prestigious national award for breakthrough in gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... there are reasons mammoths and mastodons could have been ... research from the University of Cincinnati, the famously fuzzy ... before it was trendy at the end of ... Crowley, an assistant professor of geology and anthropology, shows ... likely were year-round residents and not nomadic migrants as ...
(Date:7/21/2014)... to conserve water and save on your utility bill? ... published in the current issue of the journal ... The Most Effective Actions U.S. Households Can Take to ... use substantially by simple actions such as installing more ... While the suggestions may be familiar, the researchers are ...
(Date:7/21/2014)... Diego School of Medicine-led study suggests that parents of ... health consequences of childhood weight gain or the importance ... a healthy weight. , The study is published online ... and Dietetics . , "Parents have a hard time ... lead author Kyung Rhee, MD, and an assistant adjunct ...
Breaking Biology News(10 mins):Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3Researchers provide guide to household water conservation 2Researchers provide guide to household water conservation 3Parents rank their obese children as 'very healthy' 2
... release is available in German . , ... by the Alfred Wegener Institute for Polar and Marine ... for the first time. Polarstern left the port of ... southern course and is located right in the Northwest ...
... the Wildlife Conservation Society, Smithsonian Tropical Research Institute, National ... a new species of fisha grouper that reaches more ... 1,000 pounds. This newly discovered species can be found ... Was the massive fish hiding among the ...
... New phase 2 data published today in The ... demonstrates activity in nonsense-mutation cystic fibrosis (CF). The ... significant improvements in the chloride channel function of patients ... the Hadassah Hebrew University Hospital in Jerusalem, Israel and ...
Cached Biology News:RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
(Date:7/22/2014)... Two new members were elected to the University ... Shareholders Meeting on June 13: Kerry R. Benson, Managing ... and Stephen T. Zarrilli, President and CEO of Safeguard ... Michael A. DiPiano, Managing General Partner of New Spring ... Esq., of Duane Morris LLP, as Director Emeritus. , ...
(Date:7/22/2014)... LANSING, Mich., July 22, 2014  Neogen Corporation (NASDAQ: ... its 2014 fiscal year, which ended May 31, increased ... net income was $28,158,000, compared to the prior year,s ... 30, 2013, earnings per share in the current year ... revenues and net income for the 2014 fiscal year ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... di BGI, la maggiore organizzazione di genomica del mondo, ... di sequenziamento dell,intero esoma umano con base la piattaforma ... Complete Genomics, molto apprezzata nel settore per essere in ... 99.999% di precisione e una rilevazione altamente sensibile di ...
(Date:7/22/2014)... SHENZHEN, China , July 22, ... (BGI Tech), a subsidiary of BGI, the world,s ... of a new human whole exome sequencing service ... offered service includes in-depth bioinformatics analysis and SNP ... December 31, 2014. Complete Genomics, ...
Breaking Biology Technology:Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... Pafuramidine on Clinical Hold ... Schedule Zensana(TM) ... N.J., Dec. 28 Par,Pharmaceutical Companies, Inc. (NYSE: ... the,development status of its three, in-licensed, proprietary pipeline,products: ...
... ... merger, SOUTH SAN FRANCISCO, Calif., Dec. ... approved the proposed reverse split of its common stock by,a margin of nearly ... VaxGen to reverse split its stock in a ratio of 4,5, or 6 ...
... Program: Discriminating Real Science from Faux Science, ... recent meeting of,the Arizona Pain Society, Dominion Diagnostics ... of Urine Drug Testing:,Which Test, Which Patient and ... Robert Barkin, Pharm.D, MBA, FCP, DAAPM. Dr.,Barkin is ...
Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 2VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 3VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 4Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics 2
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Biology Products: